Breaking News

Sosei Heptares Earns $2.5M Formosa Milestone

Triggered by FDA approval of clobetasol propionate ophthalmic suspension for post-operative inflammation and pain following ocular surgery.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sosei Group Corp. announced that Formosa Pharmaceuticals, Inc. has received approval from the U.S. FDA for clobetasol propionate ophthalmic suspension 0.05% (APP13007), for the treatment of post-operative inflammation and pain following ocular surgery. The milestone has triggered a $2.5 million payment to Sosei Heptares from Formosa.   APP13007 was originally designed and developed at Activus Pharma Inc., formerly a wholly owned subsidiary of the company. Activus was divested in August 2017 to...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters